PDCD1 and melanoma: A single FMT administered colonoscopically together with PD-1 blockade successfully colonized the gut of patients and reprogrammed the tumor microenvironment to overcome primary resistance to anti-PD-1 in a subset of patients with advanced melanoma (132).